Oura’s Potential U.S. IPO: $3 Billion Raise and $16 Billion-Plus Valuation

Oura Health Oy is reportedly preparing a U.S. initial public offering that could raise as much as $3 billion and value the Finnish smart-ring maker at more than $16 billion. The listing could happen as soon as September 2026, according to reports citing people familiar with the plans, but no final terms have been announced and the timetable could change.

What is reportedly planned

The proposed transaction would combine Oura and some of its existing backers selling stock. That distinction matters: the headline $3 billion figure should not be interpreted as entirely new funding for Oura. Existing investors are expected to sell a significant amount of shares, while discussions over the structure and terms remain ongoing.

The offering’s final share count, price range and division between newly issued and existing shares have not been publicly set. Those details would be among the most important information for potential investors because they would determine how much money reaches Oura, how much ownership existing shareholders sell and how much dilution new investors face.

Oura has already filed confidentially

Oura said in May that it had confidentially submitted IPO paperwork to the U.S. Securities and Exchange Commission. The company did not disclose the number of shares or the price range, and a confidential filing does not by itself guarantee that an offering will proceed on a particular schedule.

A confidential filing allows a company to work through the SEC review process before publicly disclosing the full offering documents. Until those documents are available, investors cannot fully assess Oura’s financial performance, risks, ownership structure or the proposed use of proceeds.

The valuation would mark a sharp step up

A valuation above $16 billion would represent a significant increase from Oura’s valuation in its most recent major private financing. In September 2025, the company was reported to be raising approximately $875 million in a Series E round at a valuation of about $10.9 billion, commonly rounded to roughly $11 billion.

That would put the prospective IPO valuation more than 40% above the Series E level. The comparison is useful, but it is not a guaranteed return for private investors: a reported target is not the same as an executed public-market valuation, and the eventual price can change with market conditions and investor demand.

The reported underwriting group

Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co. and Jefferies are reported to be involved in leading the offering.

A large underwriting group can help market a transaction to institutional investors and coordinate the listing process. It does not, however, guarantee that Oura will achieve its reported valuation or complete the IPO in September.

Why Oura is a notable IPO candidate

Oura makes a ring-based wearable that tracks health, fitness and sleep metrics and provides related wellness insights. 1 Its low-profile ring design gives it a different proposition from display-focused smartwatches: users can wear a health tracker without carrying a conspicuous screen on the wrist.

That positioning has helped make smart rings a closely watched part of the wearable-health market. The category is growing and is also expected to become more crowded, creating both a larger opportunity and a tougher test for Oura’s ability to retain customers and defend its differentiation.

What the IPO would test

For Oura, a successful listing at more than $16 billion would validate the public-market case for a focused consumer health-wearables company. It could provide capital for product development and expansion while giving existing investors a route to liquidity.

The public-market test would also be demanding. Investors would likely scrutinize the company’s growth, customer retention, subscription economics, hardware margins and approach to health data and privacy. They would also need to decide whether Oura’s ring-and-software model has durable advantages as larger technology companies compete for space in consumer wearables.

For the broader consumer health-technology sector, the offering could become a valuation benchmark. The central question would be whether public investors support a substantial premium to Oura’s 2025 private-market valuation—or demand evidence that its growth and recurring-revenue potential can justify the increase. Until Oura publishes definitive offering documents, the $3 billion raise, $16 billion-plus valuation and September timing should be treated as reported possibilities rather than final IPO terms.